Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Health Sci Rep ; 6(1): e619, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36479389

RESUMO

Background and Aim: The efficacy and safety profiles of elbasvir-grazoprevir (EBR/GZR) has been established in more than 10 clinical trials. However, the characteristics of patients treated in routine clinical practice may differ. The present study was therefore designed to assess the real-life effectiveness of EBR/GZR therapy in the general population and among subgroups with a high hepatitis C virus (HCV) prevalence in France. Methods: The Zephyr study was designed as a French, multicentre, prospective, observational study on EBR/GZR use and effectiveness in current practice in chronic hepatitis C patients. These results are based on data regarding the adult patients who received at least one dose of EBR/GZR between December 2017 and June 2019 in 67 French hospitals and clinics. Results: Overall, 478 patients were included. The Full Analysis Set corresponded to the 467 patients who met all the inclusion criteria and none of the exclusion criteria. Gender was balanced and the mean age was 55.7 ± 13.3 years. The patients were mainly treatment-naive (89.5%) and infected with Genotype 1b (70.4%). Among the 75 patients with HCV Gt1a genotype, 56% had HCV RNA ≥ 800,000 IU/ml. F3-F4 fibrosis stage involved 24.2% of our population. Our subgroups were distributed among 110 migrants (23.6%), 58 (15.3%) using opioid agonist treatment, including people who inject drugs, 30 (6.8%) with chronic kidney disease Stages 3-5, 9 (1.9%) with an inherited blood disorder, and 4 (0.9%) coinfected with HIV. The remaining 269 (58.7%) were included in the general population subgroup. Overall, sustained virologic response 12 weeks after the end of treatment reached 98.0% and remained consistent among genotype, HCV RNA values, fibrosis stage, and the subgroup of interest. The rate of Alcohol Use Disorders Identification Test-Consumption​​​ and Life Habit questionnaire completion was high at each visit, with data suggesting alcohol consumption decrease and an improvement in quality of life. Conclusions: Using real-world evidence data on a French population representative of HCV patients, we confirmed the results obtained during EBR/GZR development program.

2.
BMJ Case Rep ; 20142014 May 23.
Artigo em Inglês | MEDLINE | ID: mdl-24859542

RESUMO

We report the case of a 30-year-old man with more than 100 different male sexual partners per year. He reported using cocaine, ecstasy, γ-hydroxybutyric acid and crystal mephedrone and presented with bilateral gonalgia resistant to standard analgesia. He had no noteworthy medical history, and physical examination and laboratory tests were uninformative. MRI showed marked intra-articular effusion but no meniscus or ligament damage. The aetiological diagnosis in this case was made by excluding other potential causes. Patellofemoral pain syndrome (PFPS) is one of the most common and challenging injuries. In this first case reported, the aetiology was found to be mechanical, due to the position adopted during fellatio with multiple male partners.


Assuntos
Traumatismos do Joelho/diagnóstico , Síndrome da Dor Patelofemoral/diagnóstico , Comportamento Sexual , Adulto , Humanos , Traumatismos do Joelho/etiologia , Imageamento por Ressonância Magnética , Masculino , Síndrome da Dor Patelofemoral/etiologia
3.
Clin Infect Dis ; 50(8): 1184-6, 2010 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-20210647

RESUMO

We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3-6 vaccine doses.


Assuntos
Infecções por HIV/imunologia , Anticorpos Anti-Hepatite B/sangue , Antígenos do Núcleo do Vírus da Hepatite B/imunologia , Vacinas contra Hepatite B/efeitos adversos , Vacinas contra Hepatite B/imunologia , Adulto , Feminino , Humanos , Memória Imunológica , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA